Nucleovir Therapeutics builds bespoke oncolytic viruses targeting immunologically cold tumors. The platform uses AI and wet lab loops to rationally engineer viruses for better tumor selectivity and immune activation, addressing a cancer type where virtually every conventional therapy has failed.